

**GOVERNMENT OF INDIA
MINISTRY OF AYUSH**

**RAJYA SABHA
STARRED QUESTION NO.179
TO BE ANSWERED ON 5th AUGUST 2025**

“Expert committee on Ayurvedic treatment for pancreatitis”

179. Shri A.A. Rahim

Will the Minister of *Ayush* be pleased to state:

- (a) whether Government is aware of the constitution of an expert committee by the Central Council for Research in Ayurvedic Sciences (CCRAS) and its visit to Dehradun to examine the claims made by Padma Shri Vaidya Balendu Prakash regarding the treatment of acute and chronic pancreatitis using an Ayurvedic formulation;
- (b) if so, the details of the committee’s recommendations and findings based on the visit and subsequent examination; and
- (c) whether the technical and financial assistance has been extended by CCRAS or the Ministry to implement or support the recommendations of the said expert committee?

ANSWER

**THE MINISTER OF STATE (IC) OF THE MINISTRY OF AYUSH
(SHRI PRATAPRAO JADHAV)**

(a) to (c) A Statement is laid on the Table of the House.

Statement referred to in reply to parts (a) to (c) of Rajya Sabha Starred Question No.179 due for reply on 05.08.2025 asked by Shri A.A. Rahim regarding “Expert committee on Ayurvedic treatment for pancreatitis”

(a)&(b) The Government is aware of the constitution of an Expert Committee by the Central Council for Research in Ayurvedic Sciences (CCRAS) and its visit to Dehradun to examine the claims made by Padma Shri Vaidya Balendu Prakash regarding the treatment of acute and chronic pancreatitis using an Ayurvedic formulation. The findings and recommendations of the Committee are enclosed as **Annexure-I**.

(c) No technical and financial assistance has been extended by CCRAS or the Ministry to implement or support the recommendations of the said expert committee. To prepare a comprehensive collaborative research proposal on the Treatment of Recurrent Acute/Chronic Pancreatitis through Ayurveda, a discussion was held on 16.05.2018 between Vaidya Shri Balendu Prakash of Vaidya Chandra Prakash Cancer Research Foundation and CCRAS. Subsequently, as per the provisions and guidelines of CCRAS Research Policy, consent on the following five (05) points with supporting documents was sought from Vaidya Chandra Prakash Cancer Research Foundation:-

1. Willing to share complete information on ingredients, SOPs etc.
2. Share of IPR as co-applicant if the products are already patented.
3. Willing to sign agreement/memorandum of Agreement for sharing of benefits with mutual consensus / one time lump-sum royalty.
4. Sharing of financial requirement for conducting further studies as per requirement.
5. Benefits sharing (in terms of lump-sum payment)/Annual royalty payment as per terms & conditions laid by the CCRAS.

However, Vaidya Chandra Prakash Cancer Research Foundation did not agree on two (02) points viz. (i) point no. 2 - sharing of IPR and (ii) point no. 4 - sharing of financial requirement for conducting further studies.

Keeping in view the fact that the aforesaid two points are important aspects of Administrative and IPR issues mentioned in the Benchmarks for undertaking Research as per CCRAS Research Policy and non-acceptance of the above mentioned two (02) points by Vaidya Chandra Prakash Cancer Research Foundation, CCRAS expressed its inability to take forward the referred studies with Vaidya Chandra Prakash Cancer Research Foundation. Hence, no further action was taken in the matter.

Findings and Recommendations of the Expert Committee constituted by CCRAS to examine the merit of claim made by Vaidya Shri Balendu Prakash regarding “Treatment of Recurrent Acute/Chronic Pancreatitis through Ayurveda”

In pursuance of Council’s Office Order No.344/2017-18 dated 25.08.2017, the Committee members visited Vaidya Chandra Prakash Cancer Research Foundation, Mandir Marg, Tuner Road, Clement Town, Dehrandun on 20.09.2017 to examine the merit of claim made by Vaidya Shri Balendu Prakash regarding “Treatment of Recurrent Acute/Chronic Pancreatitis through Ayurveda”. The findings and recommendations of the Expert Committee are as under:-

I. Findings of the Expert Committee

- i) Diagnosed pancreatitis patients are being admitted for first 21 days in the centre to start the treatment and after that patients have to continue the treatment for 12 months visiting the centre once in a month or as the case may be.
- ii) Vaidya Shri Balendu Prakash is treating the patients with the formulation named as “Amar” alongwith some other self prepared formulations for associated symptoms as per need like Shulvavrini Vati, Kamadudha Ras, Hingvashtak Churna, Lavangadi Vati, Muli Kshar, Navabal Rasayan, Sutashekhar Ras, Rason Vati, Dhatri Lauha etc.
- iii) The Committee interviewed 11 patients alongwith their case records who had taken treatment for 12 months period. In addition, 7 more patients admitted in the wards were also interviewed. The records of patients showed the following:-
 - a) They were diagnosed to have some form of pancreatic diseases (Chronic pancreatitis, recurrent acute pancreatitis and acute pancreatitis) by their treating doctors. That was confirmed by reviewing the documents and the radiological investigations.
 - b) During conversation, most of these patients reported that they had significant relief in their pain episodes after taking this Ayurvedic medicine. Many were pain free for many years. However, in a very of them reported recurrence of pain.
 - c) The observation of response in symptoms was based on interviewing certain number of patients who were shown to the Committee. The Committee was unable to make a definite view on the response of the drugs on their symptoms unless a systematic study is carried out.
 - d) While the symptoms improved in certain number of patients, how the pain and inflammation improved is not known.
 - e) What happened to pancreatic structure and function and pancreatic inflammation is also not known.

II. Recommendations of the Expert Committee

- i) To carry out Scientific studies and validation of the drug “AMAR” in a phased manner.
- ii) The ingredients of this compound formulation need proper standardization right from raw material to in process standardization and finally the standardization of the finished product.
- iii) Though, Vaidya Shri Balendu Prakash is prescribing the drug in the dose of 125 mg thrice a day to adult patients but dose also needs proper standardization. Since, it is a metal-based drug, safety profile must be ascertained. Therefore, toxicity study on standard experimental models is strongly recommended.
- iv) Clinical trial of the drug be carried out in a well-defined cohort of patients with chronic pancreatitis.
